Summary of the dangers
There is insufficient information on the developmental risk of RAZADYNE ER or RAZADYNE in pregnant women. At doses comparable to or greater than those used clinically, galantamine administration during pregnancy resulted in developmental toxicity (increased occurrence of morphological defects and reduced growth in offspring) in animal studies (see Data).
The estimated history risk of significant congenital disabilities and miscarriage in clinically recognized pregnancies in the general population of the United States is 2-4 percent and 15-20 percent, respectively. For the indicated population, the history risk of significant congenital disabilities and miscarriage is uncertain.
Since opioid prevention methods are still changing, it’s a good idea. It calls a poison control center to get the most up-to-date advice about handling an overdose of any medication. General supportive measures should be used in any event of an overdose. The signs and symptoms of severe galantamine overdosing are expected to be close to those of other cholinomimetics. The central nervous system, the parasympathetic nervous system, and the neuromuscular junction are all involved in these results. Symptoms of the cholinergic crisis include extreme nausea, salivation, vomiting, gastrointestinal cramping, lacrimation, urination, defecation, sweating, bradycardia, hypotension, respiratory depression, collapse, and convulsions, in addition to muscle weakness or fasciculations. Increased muscle fatigue is a possibility, and if respiratory muscles are involved, death is a possibility.
Antidotes for RAZADYNE ER and RAZADYNE (galantamine hydrobromide) overdose include tertiary anticholinergics, including atropine. An initial dose of 0.5 to 1.0 mg i.v. of intravenous atropine sulfate, titrated to effect, is prescribed, with subsequent doses dependent on clinical response. Where other cholinomimetics are combined with quaternary anticholinergics, atypical blood pressure and heart rate responses have been documented. It is unknown whether dialysis will remove galantamine and its metabolites (hemodialysis, peritoneal dialysis, or hemofiltration). Hypoactivity, tremors, clonic convulsions, salivation, mucoid feces, lacrimation, chromoda pyorrhea, and dyspnea are among the dose-related toxicity symptoms in animals.
According to a postmarketing study, one patient who had been taking 4 mg of galantamine day-to-day for a week mistakenly swallowed eight 4 mg tablets on a single day. She experienced bradycardia, QT prolongation, ventricular tachycardia, and torsades de pointes, as well as a brief loss of consciousness, which necessitated hospitalization. Two more cases of 32 mg ingestion (nausea, dry mouth and vomiting; nausea, vomiting, and substernal chest pain) and one case of 40 mg digestion (vomiting) resulted in brief hospitalizations for observation with complete recovery. One woman, who had been prescribed 24 mg/day and had a history of hallucinations in the previous two years, was given 24 mg twice daily for 34 days and experienced hallucinations that necessitated hospitalization. Another woman, who had been prescribed 16 mg of oral solution a day, accidentally swallowed 160 mg (40 mL) and developed sweating, vomiting, bradycardia, and near-syncope an hour later, necessitating hospitalization. Within 24 hours, his symptoms were gone. You can try this out if you know these things.